Gabriela Souza Carvalho
Research Subjects
Research Interests
Gabriela Souza Carvalho has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Adriano Simões Barbosa Castro
Pharmacist-Biochemist at the Department of Medicine and Nursing of the Federal University of Viçosa (UFV); Professor of medicine at the Piranga Valley Dynamic College (FADIP) Viçosa, Minas Gerais, Brazil
1 shared publication - Ana Laura Matoso da Fonseca
Medical student at Faculdade Dinâmica do Vale do Piranga (FADIP) Ponte Nova, Minas Gerais, Brazil
1 shared publication - Gabriel Filipe Rodrigues Silva Barboza
Medical student at Federal University of Viçosa (UFV) Viçosa, Minas Gerais, Brazil
1 shared publication - José Carlos Rodrigues Duarte
Medical student at Faculdade Dinâmica do Vale do Piranga (FADIP) Ponte Nova, Minas Gerais, Brazil
1 shared publication - Lyvia Mendes Ramos
Medical student at Faculdade Dinâmica do Vale do Piranga (FADIP) Ponte Nova, Minas Gerais, Brazil
1 shared publication - Marli Do Carmo Cupertino
Structural Biology Laboratory, Department of General Biology, Universidade Federal de Viçosa, Viçosa, Brazil
1 shared publication
Latest Publications
- Open Access
- 4 November 2025
- Published by Revista Brasileira de Neurologia in Revista Brasileira de Neurologia
- Vol. 61 (3)
Melatonin Use in Children and Adolescents
The widespread availability of melatonin without a prescription, combined with the lack of specific medications for certain disorders with increasing morbidity rates, is significant factors driving the rise in melatonin use over the past decade. Despite its growing popularity, uncertainties surrounding optimal dosage and duration of exposure remain critical concerns, as these factors could increase the risk of overexposure and adverse effects. This study aims to update the therapeutic indications for melatonin, as well as assess its prescription, and therapeutic strategies. An updated search was conducted utilizing the descriptors (melatonin AND (children OR child OR adolescent)). Results presents melatonin's use for sleep disorders, autism spectrum disorder, neurodevelopmental disorders, and Attention Deficit/Hyperactivity Disorder, along with a smaller number of studies exploring its therapeutic potential in conditions such as atopic dermatitis, obesity, functional abdominal pain disorders, Bipolar Affective Disorder, neurogenetic syndromes, and Bourneville disease. Pediatric-appropriate prolonged-release melatonin in correct dosages has demonstrated positive results in clinical trials and appears to be the predominant formulation. The dosage adjustment phase is crucial for successful treatment. Significant variations in dosage, adaptation time, and exposure time were observed across clinical trials, complicating the comparison of results.
- 4 November 2025
- Published by Revista Brasileira de Neurologia in Revista Brasileira de Neurologia
- Vol. 61 (3)
Open AccessMelatonin Use in Children and Adolescents
The widespread availability of melatonin without a prescription, combined with the lack of specific medications for certain disorders with increasing morbidity rates, is significant factors driving the rise in melatonin use over the past decade. Despite its growing popularity, uncertainties surrounding optimal dosage and duration of exposure remain critical concerns, as these factors could increase the risk of overexposure and adverse effects. This study aims to update the therapeutic indications for melatonin, as well as assess its prescription, and therapeutic strategies. An updated search was conducted utilizing the descriptors (melatonin AND (children OR child OR adolescent)). Results presents melatonin's use for sleep disorders, autism spectrum disorder, neurodevelopmental disorders, and Attention Deficit/Hyperactivity Disorder, along with a smaller number of studies exploring its therapeutic potential in conditions such as atopic dermatitis, obesity, functional abdominal pain disorders, Bipolar Affective Disorder, neurogenetic syndromes, and Bourneville disease. Pediatric-appropriate prolonged-release melatonin in correct dosages has demonstrated positive results in clinical trials and appears to be the predominant formulation. The dosage adjustment phase is crucial for successful treatment. Significant variations in dosage, adaptation time, and exposure time were observed across clinical trials, complicating the comparison of results.